

TENET HEALTHCARE CORP  
Form 8-K  
February 06, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report: February 5, 2019**

**(Date of earliest event reported)**

**TENET HEALTHCARE CORPORATION**  
**(Exact name of Registrant as specified in its charter)**

**Nevada**  
**(State or other jurisdiction)**

**1-7293**  
**(Commission)**

**95-2557091**  
**(IRS Employer)**

**of Incorporation)**

**File Number)**

**Identification Number)**

**1445 Ross Avenue, Suite 1400**

**Dallas, Texas 75202**

**(Address of principal executive offices, including zip code)**

**(469) 893-2200**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.

**Item 1.01. Entry into a Material Definitive Agreement.**

The information set forth below in Item 2.03 is incorporated by reference into this Item 1.01.

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

On February 5, 2019, Tenet Healthcare Corporation ( Tenet ) issued \$1,500,000,000 in aggregate principal amount of 6.250% senior secured second lien notes due 2027 (the Notes ).

The Notes were issued pursuant to an indenture, dated November 6, 2001 (the Base Indenture ), between Tenet and The Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York as trustee (in such capacity, the Trustee ), as supplemented by a supplemental indenture (the Supplemental Indenture and, together with the Base Indenture, the Indenture ), among Tenet, the guarantors party thereto, and the Trustee, dated February 5, 2019.

Tenet intends to use the net proceeds of the sale of the Notes, after payment of fees and expenses, together with cash on hand and/or any borrowings under its revolving credit agreement, to fund (i) the redemption of all \$300 million aggregate principal amount of its outstanding 6.750% Senior Unsecured Notes due February 1, 2020 (the 2020 Notes ) on February 22, 2019, (ii) the redemption of all \$750 million aggregate principal amount of its outstanding 7.500% Senior Secured Second Lien Notes due January 1, 2022 (the 2022 Notes ) on February 22, 2019 and (iii) the repayment upon maturity of all \$468 million aggregate principal amount of its outstanding 5.500% Senior Unsecured Notes due March 1, 2019.

The Indenture contains covenants that, among other things, restrict Tenet s ability and the ability of its subsidiaries to: incur liens; provide subsidiary guarantees; consummate asset sales; enter into sale and lease-back transactions; or consolidate, merge or sell all or substantially all of their assets, other than in certain transactions between one or more of Tenet s wholly owned subsidiaries and Tenet. These restrictions, however, are subject to a number of important exceptions and qualifications. In particular, there are no restrictions on Tenet s ability or the ability of its subsidiaries to incur additional indebtedness, make restricted payments, pay dividends or make distributions in respect of capital stock, purchase or redeem capital stock, enter into transactions with affiliates or make advances to, or invest in, other entities (including unaffiliated entities).

The Indenture also provides that the Notes may become subject to redemption under certain circumstances, including a change of control (as defined in the Indenture) of Tenet. Prior to February 1, 2022, Tenet may, at its option, redeem the Notes in whole or in part, at a redemption price equal to 100% of the principal amount of the Notes being redeemed plus the applicable make-whole premium set forth in the Indenture, together with accrued and unpaid interest. On and after February 1, 2022, Tenet may, at its option, redeem the Notes in whole or in part, at certain redemption prices (expressed as percentages of the principal amount thereof) set forth in the Indenture, together with accrued and unpaid interest.

In connection with the issuance of the Notes, Tenet also entered into an Exchange and Registration Rights Agreement, dated as of February 5, 2019 (the Registration Rights Agreement ), with Barclays Capital Inc. as representative of the other initial purchasers of the Notes named therein. Pursuant to the Registration Rights Agreement, in certain circumstances, Tenet has agreed to use commercially reasonable efforts to register the Notes with the Securities and Exchange Commission if the Notes have not become freely tradable (as defined in the Registration Rights Agreement) on or before the 380th day following the date hereof.

The foregoing is a summary and is qualified by reference to the Base Indenture, the Supplemental Indenture and the Registration Rights Agreement, which are filed herewith as Exhibits 4.1, 4.2, and 10.1, respectively, and are incorporated herein by reference.

**Item 8.01. Other Events.**

On January 23, 2019, Tenet issued notices of redemption to the holders of all \$300 million aggregate principal amount of the 2020 Notes and all \$750 million aggregate principal amount of the 2022 Notes. The 2020 Notes and the 2022 Notes will be redeemed on February 22, 2019.

**Item 9.01. Financial Statements and Exhibits.**

(d) The following exhibits are filed as a part of this Report.

<b>Exhibit No.</b>	<b>Description</b>
4.1	<u>Indenture dated as of November 6, 2001, between Tenet and the Bank of New York Mellon Trust Company, N.A., as successor trustee to The Bank of New York (incorporated by reference to Tenet's Current Report on Form 8-K, dated November 6, 2001 and filed November 9, 2001).</u>
4.2	<u>Thirtieth Supplemental Indenture dated as of February 5, 2019, among Tenet, the guarantors party thereto and The Bank of New York Mellon Trust Company, N.A.</u>
10.1	<u>Exchange and Registration Rights Agreement dated as of February 5, 2019, among Tenet, the guarantors party thereto and Barclays Capital Inc. as representative of the other initial purchasers of the Notes named therein.</u>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 5, 2019

TENET HEALTHCARE CORPORATION

By: /s/ Anthony Shoemaker

Name: Anthony Shoemaker

Title: Vice President, Assistant General Counsel and  
Corporate Secretary